As Johnson & Johnson navigates changing tariff landscape, execs lay out their expectations
Even as tariffs start to impact its medtech business, Johnson & Johnson is lifting its sales guidance for 2025 thanks to a recent neuroscience buyout.
Even as tariffs start to impact its medtech business, Johnson & Johnson is lifting its sales guidance for 2025 thanks to a recent neuroscience buyout.
